Grades of recovery and outcome of patients with "stroke" have been widely reported by different authors.' There is reasonable agreement on the "poor" outcome of a certain number of surviving "stroke" patients; their number is widely estimated to vary from 19% to 35%. With the growing need for physical medicine and rehabilitation treatment and the associated mushrooming financial expenditures fo...

Cyclizine (1-benzhydryl-4-methyl-piperazine, CAS 82-92-8, CYC, I), a piperazine derivative, belongs to H1 antihistamine group of drugs that shows such pharmacological properties as anti-inflammatory, anti-allergic and anti-platelet effects, similar to other H1-receptor antagonists. In this study, two new tolyl and cumene derivatives of I (1-ethyl-4-[(p-isopropylphenyl) (p-tolyl) methyl]-piperaz...

the brain edema is one of remarkable injuries after traumatic brain injuries (tbi). the common treatments for limiting edema are included mannitol, barbiturates, corticosteroids, hyperventilation and central nervous system derange. the most of these treatments for edema is problematic. for example, mannitol can be effective for the short period of time (24 hours) after brain injuries but is not...

traumatic brain injury (tbi) is one of the major causes of severe disability and death in the entire world that accidents are mentioned as main factors of it. tbi lead to primary and secondary injuries.  primary injuries are created immediately after accidents or bleeding but the secondary injuries are created by complicated process of cellular and molecular responses following primary injury a...

[no abstract available]

Cyclizine (1-benzhydryl-4-methyl-piperazine, CAS 82-92-8, CYC, I), a piperazine derivative, belongs to H1 antihistamine group of drugs that shows such pharmacological properties as anti-inflammatory, anti-allergic and anti-platelet effects, similar to other H1-receptor antagonists. In this study, two new tolyl and cumene derivatives of I (1-ethyl-4-[(p-isopropylphenyl) (p-tolyl) methyl]-piperaz...